anti-haemopexin antibody

Anti-haemopexin antibody (also referred to as anti-HPX antibody) is a therapeutic monoclonal antibody under preclinical development for the treatment of diabetic macular edema (DME) and diabetic retinopathy. Developed by the Vall d'Hebron Research Institute (VHIR) and CIBERDEM, the antibody targets and neutralizes hemopexin (HPX), a plasma heme-binding protein that is overexpressed in the vitreous fluid and retina of diabetic patients. Overexpression of hemopexin induces blood-retinal barrier (BRB) breakdown, leading to vascular leakage, neurodegeneration, and inflammation. Intravitreal administration of the anti-haemopexin antibody has been shown to significantly reduce retinal vascular permeability, prevent neurodegeneration, and inhibit microvascular angiogenesis in diabetic animal models, presenting a potential alternative or adjunctive therapy to anti-VEGF agents.

Other names

aHPXanti-HPX antibodyanti-hemopexin antibody